A new approach

CyPep-1 helps the immune system to fight cancer by exposing tumor neoantigens and inhibiting mechanisms that drive tumor growth and immune evasion.

A new
approach

CyPep-1 helps the immune system to fight cancer by exposing tumor neoantigens and inhibiting mechanisms that drive tumor growth and immune evasion.

Pipeline

AGENT: CyPep-1 // MONOTHERAPY | ALL COMERS | Ph I/II

STATUS: Fully enrolled | SPONSOR: Cytovation

AGENT: CyPep-1 // MONOTHERAPY | LIVER | Ph I

STATUS: Fully enrolled | SPONSOR: Cytovation

AGENT: CyPep-1 + Pembrolizumab // COMBINATION | ALL COMERS | Ph I

STATUS: Fully enrolled | SPONSOR: Cytovation | COLLABORATOR: Merck

AGENT: CYPEP-1 // MONOTHERAPY | ADRENOCORTICAL CARCINOMA | PH II

STATUS: Initiate 1H -24 | SPONSOR: Cytovation

AGENT: CYPEP-1 // MONOTHERAPY | COLORECTAL CANCER & HEPATOCELLULAR CARCINOMA | PH1/2

STATUS: Initiate 1H -25 | SPONSOR: Cytovation

Pipeline

PRE-CLINICAL

IND ENABLING

EARLY STAGE CLINICAL

LATE STAGE CLINICAL

AGENT: CyPep-1 // MONOTHERAPY | ALL COMERS | Ph I/II

STATUS: Fully enrolled | SPONSOR: Cytovation

AGENT: CyPep-1 // MONOTHERAPY | LIVER | Ph I

STATUS: Fully enrolled | SPONSOR: Cytovation

AGENT: CyPep-1 + Pembrolizumab // COMBINATION | ALL COMERS | Ph I

STATUS: Fully enrolled | SPONSOR: Cytovation | COLLABORATOR: Merck

AGENT: CYPEP-1 // MONOTHERAPY | ADRENOCORTICAL CARCINOMA | PH II

STATUS: Initiate 1H -24 | SPONSOR: Cytovation

AGENT: CYPEP-1 // MONOTHERAPY | COLORECTAL CANCER & HEPATOCELLULAR CARCINOMA | PH1/2

STATUS: Initiate 1H -25 | SPONSOR: Cytovation